Immuno-Oncology and the Need to Review Drug Development By Diana Roettger, PhD Head of R&D
Immuno-Oncology drugs are considered as a breakthrough in cancer treatment because of their ability to target and enable immune cells to destroy cancer cells. Immunotherapies force us not only to review cancer treatment but also drug development.
The immune system is the body’s natural defence system, attacking dangerous cells and ...
Muscle Perfusion as a Unique Biomarker for in Clinical Trials Skeletal muscle can adapt to various stimuli. Physical activity and exercise represent different types of stresses to the muscle. Depending on the exact nature of the stress, muscle may increase in size, improve neuro-muscular performance and enhance endurance capabilities. This brief overview gives an introduction into the clinical research conducted by IA-Group and collaborators into ...
Use of Gadolinium Based Contrast Agents – What, Why and What Is Next? On the 10th March, EMA’s Pharmacovigilance and Risk Assessment Committee (PRAC) has recommended the suspension of the marketing authorizations for four linear gadolinium contrast agents because of evidence that small amounts of the gadolinium they contain are deposited in the brain. There are no signs of harm to the patient health.
This recommendation provoked a lot ...
Liver Imaging and Quantitative Biomarkers in Clinical Trials Liver biopsy is a standard procedure for diagnosing and staging non-alcoholic fatty-liver disease. However, biopsy has a number of disadvantages, including sampling error, intra- and inter-rater variability and poor patient acceptance due to potential complications. Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide.
Quantitative imaging is a promising approach for evaluating ...
I feel strongly that by making Dynamika available, student researchers could come up with very interesting and meaningful quantitative projects. Laura, Radiographer
We have been using Dynamika software to analyse DCE data as part of a research project using multiparametric MRI for targeted radiotherapy treatment planning. We have found the software extremely useful compared with software delivered with our MRI scanner for a number of reasons, in particular: the ability to control each stage of the data processing, the ability to assess image quality and examine the parametric and pharmacokinetic maps in detail. Our project requires a quantitative (rather than qualitative) analysis of the DCE data and we have been very impressed with the collaborative approach of the Image Analysis support team in helping us achieve our goals. In addition, we commend the support team in providing informative and responsive training sessions and willingness to develop the software to meet the needs of our research project. Hayley Reynolds, Research Fellow, The Peter MacCullum Cancer Centre, Melbourne, Australia
I am a clinical-research fellow with high experience in prostate MRI analysis and reporting. I have been using Dynamika mostly to help the analysis support team to develop a PI-RADS structured reporting user interface.
The software is extremely useful and has the potential to be used in daily clinical practice. One of the most important skills of Dynamika is the capability of providing high quality tools to report prostate mpMRIs together with the possibility of assessing quantitative analysis at the same time.
Therefore, Dynamika opens a new window in the use of automated and semi-automated algorithms both for clinical and research purposes.
The integration of these two aspects is further strengthened by the remarkable competence of the support team that is constantly willing to help me when necessary.
I hope to keep on working with Dynamika and taking advantage of all its valuable tools during my clinical-research practice. Francesco Giganti- Clinical Research Fellow, University College Hospital, London, UK
Dynamika is really fantastic! Salvatore Costantino, Post Doctoral Researcher, University of Sassari, Italy
Dynamika is key to precise and accurate early diagnostics and a powerful tool for follow-up of post-op and post chemo and/or radio treatment patients. Roman Marin, Head of CT and MRI Department